Please ensure Javascript is enabled for purposes of website accessibility

Novavax Crushed the Broader Markets in 2015 -- Here's Why

By George Budwell - Jan 12, 2016 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax turned in another strong year in 2015. Read on to find out why.

NVAX Chart

What: According to S&P Capital IQ, shares of the clinical-stage vaccine company Novavax (NVAX 2.68%) gained more than 45% last year, crushing the annual performance of the broader stock market and the industry-specific iShares Nasdaq Biotechnology ETF (IBB 2.41%). The company's strong annual performance is the direct result of the rapid progress of its experimental vaccine for respiratory syncytial virus, or RSV, indicated for pediatric and older patients. Over the course of 2015, for instance, Novavax reported promising mid-stage results in infants and initiated a late-stage study in older adults.

So what: Beside inching ever closer to transforming into a commercial operation after launching a pivotal stage study, Novavax was also able to shore up its balance sheet last year via an $89 million grant from the Gates Foundation. This grant will support the vaccine's further development in pregnant women.

Now what: Per a recent investor presentation, Novavax is planning on launching a second late-stage study for this vaccine in pregnant women in the first quarter of 2016. Given how quickly this vaccine has worked its way through the clinical testing process so far, there's a good chance Novavax could end up filing for the vaccine's approval for two high-dollar indications in 2017.

Commercially speaking, this experimental RSV vaccine is thought to have megablockbuster potential in light of the fact that there are over 37 million cases of RSV per year in just the major markets in Asia, the EU, and the U.S. alone. So, despite Novavax's monstrous 2015, investors shouldn't be surprised if this stock outperforms the IBB again in 2016, and easily surpasses the performance of the broader markets as well. 

Of course, the potential downside risk is that something goes wrong during the vaccine's late-stage testing, dashing its hopes for a regulatory approval in the process. The good news is that this vaccine has already been tested in several fairly large mid-stage trials at this point, and it's looked great from a safety and efficacy standpoint for the most part -- although some analysts have questioned the vaccine's ability to confer maternal immunity to unborn infants.

All told, Novavax appears worthy of a deeper dive by seasoned biotech investors who understand the risks inherent in any clinical-stage company. 

George Budwell owns shares of iShares NASDAQ Biotechnology Index (ETF). The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.36 (2.68%) $1.08
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$133.04 (2.41%) $3.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.